低剂量静脉与皮下注射CIS43LS单克隆抗体预防疟疾(VRC 612 C部分):一项1期适应性试验
VRC 612 C部分是一项在美国马里兰大学巴尔的摩疫苗开发与全球健康中心开展的首人体1期适应性试验,纳入31名无疟疾疫苗或感染史的18-50岁成人,评估CIS43LS单克隆抗体1、5、10 mg/kg静脉或5、10 mg/kg皮下注射的安全性及对控制性人疟感染的保护效果。CIS43LS安全且耐受良好,无严重不良事件,5和10 mg/kg静脉或皮下注射组均未出现寄生虫血症,1 mg/kg静脉组7人中有4人出现寄生虫血症,6名对照全部出现寄生虫血症。
要点
- CIS43LS在1-10 mg/kg静脉或5-10 mg/kg皮下注射时安全耐受良好,无严重不良事件。
- 5和10 mg/kg静脉或皮下注射组受试者均未发生寄生虫血症。
- 1 mg/kg静脉组7人中4人出现寄生虫血症,6名对照全部出现寄生虫血症。
核心结论
- CIS43LS安全且耐受良好,在低剂量和皮下途径下对恶性疟原虫提供保护,提示该方法可能适用于多种临床场景预防疟疾。
研究设计与样本
- VRC 612 C部分是一项在美国马里兰大学巴尔的摩疫苗开发与全球健康中心开展的首人体1期适应性试验,采用序贯剂量递增方式纳入31名18-50岁无疟疾疫苗或感染史的成人。
- 受试者单次开放标签接受CIS43LS 1 mg/kg(n=7)、5 mg/kg(n=4)或10 mg/kg(n=3)静脉注射,或5 mg/kg(n=4)或10 mg/kg(n=4)皮下注射,另有8名对照未接受CIS43LS。
- 接种后约8周通过5只感染恶性疟原虫3D7株的蚊虫叮咬进行控制性人疟感染,第7-18天及第21天每日随访,采用定性PCR检测恶性疟原虫。
主要发现
- CIS43LS给药安全且耐受良好,未发生严重不良事件。
- CIS43LS在22名接受给药的受试者中保护了18人(82%)。
- 5 mg/kg静脉或皮下注射组以及10 mg/kg静脉或皮下注射组均无受试者出现寄生虫血症。
- 1 mg/kg静脉注射组7人中有4人出现寄生虫血症,6名对照全部出现寄生虫血症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human monoclonal antibodies might offer an important new approach to reduce malaria morbidity and mortality. In the first two parts of a three-part clinical trial, the antimalarial monoclonal antibody CIS43LS conferred high protection against parasitaemia at doses of 20 mg/kg or 40 mg/kg administered intravenously followed by controlled human malaria infection. The ability of CIS43LS to confer protection at lower doses or by the subcutaneous route is unknown. We aimed to provide data on the safety and optimisation of dose and route for the human antimalaria monoclonal antibody CIS43LS. METHODS: VRC 612 Part C was the third part of a three-part, first-in-human, phase 1, adaptive trial, conducted at the University of Maryland, Baltimore Center for Vaccine Development and Global Health, Baltimore, MD, USA. We enrolled adults aged 18-50 years with no previous malaria vaccinations or infections, in a sequential, dose-escalating manner. Eligible participants received the monoclonal antibody CIS43LS in a single, open-label dose of 1 mg/kg, 5 mg/kg, or 10 mg/kg intravenously, or 5 mg/kg or 10 mg/kg subcutaneously. Participants underwent controlled human malaria infection by the bites of five mosquitoes infected with Plasmodium falciparum 3D7 strain approximately 8 weeks after their monoclonal antibody inoculation. Six additional control participants who did not receive CIS43LS underwent controlled human malaria infection simultaneously. Participants were followed-up daily on days 7-18 and day 21, with qualitative PCR used for P falciparum detection. Participants who tested positive for P falciparum were treated with atovaquone-proguanil and those who remained negative were treated at day 21. Participants were followed-up until 24 weeks after dosing. The primary outcome was safety and tolerability of CIS43LS at each dose level, assessed in the as-treated population. Secondary outcomes included protective efficacy of CIS43LS after controlled human malaria infection. This trial is now complete and is registered with ClinicalTrials.gov, NCT04206332. FINDINGS: Between Sept 1, 2021, and Oct 29, 2021, 47 people were assessed for eligibility and 31 were enrolled (one subsequently withdrew and was replaced) and assigned to receive doses of 1 mg/kg (n=7), 5 mg/kg (n=4), and 10 mg/kg (n=3) intravenously and 5 mg/kg (n=4) and 10 mg/kg (n=4) subcutaneously, or to the control group (n=8). CIS43LS administration was safe and well tolerated; no serious adverse events occurred. CIS43LS protected 18 (82%) of 22 participants who received a dose. No participants developed parasitaemia following dosing at 5 mg/kg intravenously or subcutaneously, or at 10 mg/kg intravenously or subcutaneously. All six control participants and four of seven participants dosed at 1 mg/kg intravenously developed parasitaemia after controlled human malaria infection. INTERPRETATION: CIS43LS was safe and well tolerated, and conferred protection against P falciparum at low doses and by the subcutaneous route, providing evidence that this approach might be useful to prevent malaria across several clinical use cases. FUNDING: National Institute of Allergy and Infectious Diseases, National Institutes of Health.
引用
- Lyke KE, Berry AA, Mason K, et al. Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial. Lancet Infect Dis. 2023. PMID: 36708738. doi:10.1016/S1473-3099(22)00793-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。